Sept 26 (Reuters) - Enanta Pharmaceuticals Inc :
* ENANTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FOR EDP-323 IN A PHASE 2A HUMAN CHALLENGE STUDY OF HEALTHY ADULTS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
* ENANTA PHARMACEUTICALS INC - EDP-323 ACHIEVES SIGNIFICANT REDUCTIONS IN VIRAL LOAD AND SYMPTOMS
* ENANTA PHARMACEUTICALS INC: FAVORABLE SAFETY AND TOLERABILITY OBSERVED
* ENANTA PHARMACEUTICALS INC: TREATMENT WITH ONCE-DAILY EDP-323 MET PRIMARY AND SECONDARY ENDPOINTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.